MECCA: Method of Clopidogrel Pre-treatment Undergoing Conventional Coronary Angiogram in Angina Patients

Sponsor
Korea University Anam Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03759067
Collaborator
(none)
511
3
33.4

Study Details

Study Description

Brief Summary

The study included 511 patients who underwent PCI because of angina during 2010-2011 at three Korean hospitals. Clopidogrel-naïve patients received either a loading dose (LD; 600 mg at 2-24 h before the procedure) or routine maintenance therapy (75 mg/day for ≥5 days) plus either a 300-mg reload (RL) or only the maintenance dose (MD).

Condition or Disease Intervention/Treatment Phase
  • Drug: clopidogrel 75mg
  • Drug: Clopidogrel 300 mg
  • Drug: clopidogrel 600mg
N/A

Detailed Description

Elevation of myocardial infarction markers after coronary stenting reflects periprocedural myonecrosis or periprocedural myocardial infarction (PMI), which is associated with an increase in cardiac events and mortality. Thus, we aimed to evaluate various clopidogrel pre-treatment methods for preventing PMI among patients undergoing conventional CAG for stable angina pectoris. The Method of Clopidogrel Pre-treatment Undergoing Conventional Coronary Angiogram in Angina patients (MECCA) study was a prospective, partially randomized, multi-center clinical trial. Between October 2010 and July 2011, 511 patients underwent PCI for angina pectoris at the Korean University Anam Hospital, the Eulji Hospital, and the Hanil General Hospital. Clopidogrel-naïve patients were enrolled to receive a loading dose (the LD group; clopidogrel at 600 mg, usually 2-24 h before the procedure) or routine therapy using daily clopidogrel doses (75 mg/day for ≥5 days). Patients receiving daily doses were randomized to receive either an additional 300-mg reload (the RL group) or no additional loading (the maintenance dose [MD] group). The 600-mg or 75-mg treatment regimens were selected at the physician's discretion. The primary outcome was creatinine kinase myocardial band (CK-MB) levels at several time points. The CK-MB levels were measured at baseline, 8 h, and 24 h, while troponin-I levels were measured at 8 h after the PCI.

Study Design

Study Type:
Interventional
Actual Enrollment :
511 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prospective Partially Randomized Comparison of Clopidogrel Loading Versus Maintenance Dosing to Prevent Periprocedural Myocardial Infarction After Stenting for a Stable Angina Pectoris
Actual Study Start Date :
Oct 18, 2010
Actual Primary Completion Date :
Jan 31, 2012
Actual Study Completion Date :
Jul 31, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: LD group

clopidogrel 600 mg once loading, usually 2-24 h before the procedure

Drug: clopidogrel 600mg
clopidogrel 600mg loading
Other Names:
  • LD
  • Experimental: MD group

    After randomization, the routine therapy using daily clopidogrel 75mg

    Drug: clopidogrel 75mg
    clopidogrel once daily 75mg
    Other Names:
  • MD
  • Active Comparator: RL group

    After randomization, additional clopidogrel 300 mg reloading for patients who were taking a maintenance dose.

    Drug: clopidogrel 75mg
    clopidogrel once daily 75mg
    Other Names:
  • MD
  • Drug: Clopidogrel 300 mg
    clopidogrel 300mg reloading
    Other Names:
  • RL
  • Outcome Measures

    Primary Outcome Measures

    1. 8hour mean CK-MB [8hour after PCI]

      mean CK-MB(creatinine kinase myocardial band) is checked 8hour after PCI

    2. 24hour mean CK-MB [24hour after PCI]

      mean CK-MB(creatinine kinase myocardial band) is checked 8hour after PCI

    Secondary Outcome Measures

    1. 8hour mean troponin-I [8hour after PCI]

      mean troponin-I is checked 8hour after PCI

    2. Prevalence of periprocedural myocardial infarction (PMI) [8hour or 24hour after PCI]

      Patients were considered to have PMI when their CK-MB level was elevated to >3 times the upper limit of normal, which was defined as 4.94 ng/mL.

    3. All cause death [9 months after PCI]

      All death is evaluated using chart reviews and telephone calls.

    4. Coronary revascularization [9 months after PCI]

      Coronary revascularization is evaluated using chart reviews and telephone. calls.

    Other Outcome Measures

    1. Moderate to severe GUSTO bleeding [within 1week after PCI]

      Moderate GUSTO bleeding is defined as bleeding that requires blood transfusion but does not result in hemodynamic compromise. severe GUSTO bleeding is defined as a intracranial hemorrhage or hemodynamic compromise requiring treatment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Written informed consent and, stable angina pectoris and, at least 1 ischemic evidence below
    1. Treadmil test positive

    2. ST-T change in resting ECG or 24-hour ECG

    3. Regional wall motion abnormality in Echocardiography or cardiac MRI

    4. Myocardial ischemia at MIBI scan

    5. moderate to severe stenosis at coronary CT angiography

    6. chest pain or dyspnea

    Exclusion Criteria:
    • AST or ALT > 3 times upper normal limits

    • Serum creatinine > 2.0 mg/dL

    • chronic malaborption status (disorder or operation)

    • planned surgery within 1 year

    • pregnancy or breast-feeding patients

    • life expectancy < 1 year

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Korea University Anam Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Do-sun Lim, Professor, Korea University Anam Hospital
    ClinicalTrials.gov Identifier:
    NCT03759067
    Other Study ID Numbers:
    • KUMC_MECCA
    First Posted:
    Nov 29, 2018
    Last Update Posted:
    Nov 29, 2018
    Last Verified:
    Nov 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Do-sun Lim, Professor, Korea University Anam Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 29, 2018